Skip to main content
Premium Trial:

Request an Annual Quote

What a Result! Wait, a Second...

Highly-cited biomarker studies tend to report larger effect estimates for associations than subsequent meta-analyses do, says a literature review published in the Journal of the American Medical Association. John Ioannidis and Orestis Panagiotou combed through the ISI Web of Science to find studies that had been cited more than 400 times and had been published in a highly cited journal, and they searched for meta-analyses of those studies. From this, they evaluated 35 highly cited associations. "For 30 of the 35 (86%), the highly cited studies had a stronger effect estimate than the largest study; for 3 the largest study was also the highly cited study; and only twice was the effect size estimate stronger in the largest than in the highly cited study," Ioannidis and Panagiotou write. Ioannidis tells [email protected] that "the key message is that results that seem spectacular are very interesting, but researchers need to wait for further validation from independent research teams and large-scale evidence."

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.